
    
      The study consists of 2 periods: a 6 month Treatment Period and a post treatment follow-up
      period of up to 12 months.

      Participants who received elagolix in the pivotal study who met all entry criteria continued
      to receive the same dose, either elagolix 150 mg once daily (QD) or elagolix 200 mg twice
      daily (BID) for up to an additional 6 months in this extension study; participants who
      received placebo in the pivotal study were randomized in a 1:1 ratio to receive either
      elagolix 150 mg QD or elagolix 200 mg BID for up to 6 months.

      An electronic diary will be used to collect endometriosis-associated pain, uterine bleeding,
      and analgesic medication use for endometriosis associated pain on a daily basis.
    
  